Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Bully88on May 25, 2021 11:38am
124 Views
Post# 33259985

RE:RE:Fundamentally I like the Stock

RE:RE:Fundamentally I like the Stock10,000 was a number derived from statements made from their aquisition.

not just a blue sky number out of thin air.

not a guess. facts.

they have access to 10,000 patients.

are they going to test all 10,000  people in a year? most definitely not.

the point of my post was to show that the potential for revenue growth is there.

Also. Technically speaking, going 11 decimal places does make it more accurate... by 11 decimal points.

I have never once mentioned my expected number of tests completed.
 
merely given the chart for people to look at so that when szls released numbers. we as interested investors can look back at it and see where they are in relation to testing numbers.


cheers,

Bully


<< Previous
Bullboard Posts
Next >>